Maze Therapeutics CEO Jason Coloma Sells 84,501 Shares

What Happened

• Jason V. Coloma, CEO of Maze Therapeutics (MAZE), sold a total of 84,501 shares on September 1, 2026. This includes two open-market sales (2,593 shares and 31,908 shares) and a conversion/exercise of a derivative involving 50,000 shares that were also disposed of per the filing.
• Open-market proceeds reported: $68,214 (2,593 shares at $26.31) and $838,785 (31,908 shares at a $26.29 weighted average), totaling about $906,999 (~$907k). The derivative exercise/conversion entries are reported at $0.00 in the filing.

Key Details

• Transaction date: September 1, 2026; Form 4 filed September 3, 2026.
• Open-market sales: 2,593 shares @ $26.31 ($68,214) and 31,908 shares @ $26.29 (weighted avg, $838,785). Reported sale price ranges: $26.14–$26.50 and $26.13–$26.555 per footnotes.
• Derivative activity: Exercise/conversion of 50,000 shares (acquired at $0.00) and disposition of 50,000 shares (reported at $0.00) — filing shows these as derivative/option conversion entries.
• Shares owned after transaction: Not specified in the information provided here (see the full Form 4 for total beneficial ownership).
• Notable footnotes: sale executed under a Rule 10b5‑1 trading plan adopted Feb 6, 2026 (F1); certain shares are held by family trusts for which Coloma and his spouse are co-trustees (F3, F5); weighted-average pricing reported with price ranges and offering to provide per-price details on request (F2, F4); restricted-stock-unit notes appear in the filing (F6–F8).
• Filing timeliness: Transactions dated Sep 1 and Form 4 filed Sep 3 — no late filing flag indicated in the provided data.

Context

• The filing shows sales rather than net purchases. The derivative entries suggest a conversion/exercise and immediate disposition (common in cashless exercises), but the filing reports $0 for those derivative entries — see the full Form 4 for the exact mechanics. Sales executed under a pre-established 10b5‑1 plan are often automated and do not by themselves indicate a change in insider sentiment.